Clinical trials

Condition   Drug Name  
Study Adalimumab in psoriasis: The REVEAL (Randomized Controlled Evaluation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis Trial
Design Randomized; Double-blind; Multicenter
Patients 1212
Treatment Regimen Adalimumab, 80 mg s.c. --> 40 mg s.c. 1x/2 wks x 15 wks (n=814); Placebo (n=398)
Conclusions Responses to adalimumab occurred quickly and the agent was well tolerated in patients with psoriasis
Reference(s) Adalimumab efficacy and safety in patients with moderate to severe psoriasis: Results from the first 16 weeks of REVEAL
16th Congr Eur Acad Dermatol Venereol (EADV) (May 16 2007 , Vienna) 2007:Abst P1154.
Author and Affiliation Menter, A., Papp, K., Leonardi, C., Okun, M.